Overview
Retatrutide is an investigational single-molecule triple agonist associated with the GIP, GLP-1, and glucagon receptors. The catalogue lists a 20 mg lyophilized reference format.
Research use onlySpecification publishedQualified users only
Metabolic & incretin research · AGX-01
Retatrutide
The triple-pathway metabolic candidate
$120
20 mg lyophilized vial$6.00/mg · research use only
Research use only · no human or veterinary use, consumption, administration, diagnosis, treatment, prevention, cosmetic use, or food use. Sold to qualified laboratory and analytical users.
Mechanism (research literature)
The term triple agonist describes receptor activity at GIP, GLP-1, and glucagon receptors. These receptor classes are the basis of its classification in incretin research.
Research context
Retatrutide appears in metabolic and incretin receptor literature.
Specification
Listed format20 mg lyophilized vial
Sequence39-residue triple agonist
Molecular formulaNot a discrete formula
Molecular weight≈4731 g/mol
Catalogue referenceAGX-01
Listed price$120
StatusInvestigational research compound
Common questions
What does triple agonist mean?
It describes a molecule with agonist activity at three receptor types; this record identifies GIP, GLP-1, and glucagon receptors.
Is Retatrutide approved for use?
No. It is an investigational compound supplied for laboratory research use only, with no human or animal-use indication.